170 related articles for article (PubMed ID: 36787255)
41. Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer.
Tan Y; Chen H; Zhang J; Cai L; Jin S; Song D; Yang T; Guo Z; Wang X
Eur J Med Chem; 2022 Feb; 229():114047. PubMed ID: 34915428
[TBL] [Abstract][Full Text] [Related]
42. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
43. Structural-functional diversity of CD47 proteoforms.
Zhang T; Wang F; Xu L; Yang YG
Front Immunol; 2024; 15():1329562. PubMed ID: 38426113
[TBL] [Abstract][Full Text] [Related]
44. Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.
Hu J; Xiao Q; Dong M; Guo D; Wu X; Wang B
Front Immunol; 2020; 11():593219. PubMed ID: 33329583
[TBL] [Abstract][Full Text] [Related]
45. Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies.
Wang C; Sallman DA
Curr Opin Hematol; 2022 Jan; 29(1):44-52. PubMed ID: 34854834
[TBL] [Abstract][Full Text] [Related]
46. The CD47-SIRPα Immune Checkpoint.
Logtenberg MEW; Scheeren FA; Schumacher TN
Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
[TBL] [Abstract][Full Text] [Related]
47. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
48. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
49. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
50. Quantitatively Lighting up the Spatial Organization of CD47/SIRPα Immune Checkpoints on the Cellular Membrane with Single-Molecule Localization Microscopy.
Wei Y; Zhao M; He T; Chen N; Rao L; Chen L; Zhang Y; Yang Y; Yuan Q
ACS Nano; 2023 Nov; 17(21):21626-21638. PubMed ID: 37878521
[TBL] [Abstract][Full Text] [Related]
51. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
52. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
[TBL] [Abstract][Full Text] [Related]
53. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
54. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
[No Abstract] [Full Text] [Related]
55. CD47-SIRP
Catalán R; Orozco-Morales M; Hernández-Pedro NY; Guijosa A; Colín-González AL; Ávila-Moreno F; Arrieta O
J Immunol Res; 2020; 2020():9435030. PubMed ID: 33015199
[TBL] [Abstract][Full Text] [Related]
56. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Andrejeva G; Capoccia BJ; Hiebsch RR; Donio MJ; Darwech IM; Puro RJ; Pereira DS
J Immunol; 2021 Feb; 206(4):712-721. PubMed ID: 33431660
[TBL] [Abstract][Full Text] [Related]
57. The development of small-molecule inhibitors targeting CD47.
Yu WB; Ye ZH; Chen X; Shi JJ; Lu JJ
Drug Discov Today; 2021 Feb; 26(2):561-568. PubMed ID: 33197622
[TBL] [Abstract][Full Text] [Related]
58. Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Liu X; Liu L; Ren Z; Yang K; Xu H; Luan Y; Fu K; Guo J; Peng H; Zhu M; Fu YX
Cell Rep; 2018 Aug; 24(8):2101-2111. PubMed ID: 30134171
[TBL] [Abstract][Full Text] [Related]
59. Novel CD47: SIRPα dependent mechanism for the activation of STAT3 in antigen-presenting cell.
Toledano N; Gur-Wahnon D; Ben-Yehuda A; Rachmilewitz J
PLoS One; 2013; 8(9):e75595. PubMed ID: 24073274
[TBL] [Abstract][Full Text] [Related]
60. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
